TargeGen, Inc. Appoints Martin Friedlander, M.D., Ph.D. to Scientific Advisory Board
SAN DIEGO, April 12 /PRNewswire/ -- TargeGen, Inc. today announced the appointment of Martin Friedlander M.D., Ph.D. to its Scientific Advisory Board.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)
Dr. Friedlander currently serves as a Professor of Cell Biology at the Scripps Research Institute (La Jolla, CA) and is a Staff Ophthalmologist and Chief of the Retina Service at Scripps Clinic and Green Hospital. Dr. Friedlander earned his Ph.D. from the University of Chicago and his M.D. from the State University of New York, Downstate Medical Center. Dr. Friedlander is well known for his research achievements relating to the role of angiogenesis in debilitating diseases of the eye and the development of novel therapeutic approaches, including the use of progenitor cells, for the treatment of ocular neovascular diseases such as macular degeneration and diabetic retinopathy.
"We are extremely pleased to have someone of Dr. Friedlander's stature in the field of ocular diseases join our Scientific Advisory Board and his appointment reflects our increasing commitment toward the development of meaningful new therapeutic approaches for the treatment of macular degeneration, diabetic retinopathy and other debilitating diseases of the eye," said Peter G. Ulrich, President and CEO of TargeGen.
About TargeGen, Inc.
TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen has recently completed a successful Phase I clinical trial involving TG100801, the first topically applied (eye drop) kinase inhibitor for the treatment of AMD. TargeGen plans to initiate Phase II trials in AMD patients with TG100801 in the second half of 2007. Additionally, the Company is developing a second, preclinical, topical compound TG100948 for the treatment of diabetic macular edema.
TargeGen has received financial backing to date from first tier venture investors including Forward Ventures, Enterprise Partners, Chicago Growth Partners, Vantage Point Venture Partners, BB BIOTECH, Hambrecht & Quist Capital Management, Pappas Ventures, and other investors.
Photo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comTargeGen, Inc.CONTACT: TargeGen, Inc., +1-858-678-0760, or fax, +1-858-678-0762,ulrich@targegen.com
Web site: http://www.targegen.com/